

Key Investor Information Document (KIID)

Target document

This document provides you with essential information about this investment product. It is not marketing material. This information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Ordinary shares (the "Shares") in the capital of ALS Invest 7 B.V. (the "Fund"), an investment company under Dutch law managed by SUNU Ventures B.V. ("Administrator"). More information is available at www.alsinvestmentfund.com or you can send an email to admin@alsinvestmentfund.com. The Netherlands Authority for the Financial Markets (AFM) is responsible for supervising the Manager in connection with this document. The production date of this EID is December 2, 2020.

You are about to purchase a product that is not simple and may be difficult to understand.

What is this product?

Kind

The Fund is a private company with limited liability under Dutch law and qualifies as an alternative investment funds (ABI) under the AIFM Directive (Alternative Investment Fund Managers Directive (EU/2011/61)).

Goals

The Fund will invest the funds to be obtained from its investors in the shares (the "Underlying Asset") of Prilenia Inc.. ("Company"), a Dutch / Israeli biotech company focused on developing a drug against ALS and other neurological diseases. The Fund aims to benefit from an increase in the Underlying Value and make a social impact for patients with neurodegenerative diseases, especially ALS. The Fund can capitalize on this value development through a takeover, merger or IPO of the Underlying Asset or through possible profit distributions (dividend). The latter is not likely for development stage biotechs. The return of the Fund is determined by this income, reduced by the various costs as described later in this document.

Retail investor at whom the product is targeted

The product is aimed at the retail investor who invests for the long term and offers the opportunity investing in a private biotech company and thereby benefiting from a possible increase in value, as well as making a social impact for patients with neurodegenerative diseases and ALS in particular. The investment is a high-risk profile, investors may lose all or part of their investment. Suited for investors that have at least some knowledge and/or experience with venture capital investments and can bear losses (up to the maximum of his invested amount).

Duration

In principle, the fund has a term of 5 years after a 5-year investment period, but can be liquidated at any time by 75% of the voting shareholders in the Fund. The term can be extended by the manager by 1 year and subsequently by a maximum of 1 year by a majority of the voting shareholders in the fund. The Fund will be liquidated after the investment is sold.

What are the risks and what can I get in return?

Risk indicator



The risk indicator assumes that you entered the Fund during the initial closing and that you hold the product for the lifetime of the Fund. The actual risk can vary significantly if you cash in at an early stage and you may get back less than the amount invested. You may not be able to sell your holdings easily or you may have to sell at a price that is significantly less than anticipated or significantly impacts on the total return achieved.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because you are not able to realize any value from your shares. The risk category shown is not guaranteed and may change over time. The lowest category does not mean it is risk free. We have classified this product as 7 out of 7; that is the highest risk class. This means that the potential losses on future performance are estimated to be "very high" due to the nature of the investment which will be in an unquoted private company whose shares may be difficult to sell or market. Such shares may have risks associated with them greater than quoted securities or shares. Restrictions may apply to the transfer of shares in the private company in which the Fund invests. The timing of any realization cannot be predicted and proper information for calculating the current value of the Fund's investment or the degree of risk posed may not be available.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance Scenarios (Single Deposit)

Investment EUR 10.000		year 1	year 5	year 10 (recommended holding period)
Stress Scenario	What you might get back after costs	EUR 0	EUR 0	EUR 0
	Average return each year	-100,0%	-100,0%	-100,0%
Unfavourable Scenario	What you might get back after costs	EUR 9.432	EUR 8.408	EUR 8.377
	Average return each year	-5,7%	-3,4%	-1,8%
Moderate Scenario	What you might get back after costs	EUR 10.847	EUR 17.500	EUR 35.153
	Average return each year	8,5%	11,8%	13,4%
Favourable Scenario	What you might get back after costs	EUR 11.318	EUR 21.820	EUR 54.241
	Average return each year	13,2%	16,9%	18,4%

*period = interest % per year

This table shows the money you could get back over the next 10 years, under different scenarios, assuming that you invest EUR 10,000 at the initiation of the fund. The scenarios shown illustrate the potential return on your investment. You can compare these scenarios with scenarios from other products. The scenarios shown are an estimate of future performance based on past data on how the value of this investment could vary, and are not an exact projection. What you receive depends on how the underlying company performs and at what time you entered. What you get will depend on how the market performs and how long you hold the investment/product. The stress scenario shows what you could get back in extreme market conditions and does not take into account the situation where we are unable to pay you. The amounts shown include all costs of the product itself, but may not include all costs you pay to your advisor or distributor. The amounts do not take into account your personal tax situation, which may also affect how much you get back.

What happens if the Fund is unable to pay out?

You may lose all or part of your investment if the Fund has insufficient funds to meet its payment obligations under the product. This loss is not covered by any investor compensation or guarantee scheme.

What are the costs?

The amounts shown in the table above are the cumulative costs of the product itself. Potential penalties for knowingly early exit are included. The amounts are based on the assumption that you invest EUR 10.000. The numbers are estimates and may change in the future.

Investment Scenario (moderate) EUR 10.000	If you sell after (1) year	If you sell after (the recommended period of holding /2)	If you sell at the end of the recommended period of holding
Total cost	-€624	-€2.774	-€6.329
Impact on return (RIY) per year	-44,1%	-30,5%	-23,6%

The person who sells you this product or who advises you about this product may charge you other costs. In that case, that person will provide you with information about those costs and show you how all the costs will affect your investment over time.

Composition of the costs

The table shows the effect each year of the different types of charges on your potential return on investment at the end of the recommended holding period and the significance of the different cost categories.

The tabel indicates the impact of costs on return per year			
One off costs	Entry cost (pro rata)	€12.100	The impact of the costs you pay when entering your investment. This is the most you will pay, and you could pay less.
	Exit cost	n.a.	The impact of the costs of exiting your investment when it matures.
Ongoing costs	Portfolio transaction costs (one off)	3,00%	The impact of the costs of us buying and selling underlying investments for the product.
	Other ongoing cost (annual)	€6.050	The impact of the costs that we take each year for bank, legal and otyher direct costs, taxes are covered by the fund
	Performance fee (annual)	2,50%	The impact of the costs that we take each year for managing your investment
Incidental costs	Carried interest	20% of your proceeds	The impact of carried interest. We charge this only once the full amount of the original Subscription plus one off costs and ongoing costs have been returned to you.

How long should I keep it and can I get money out sooner?

Recommended or minimum holding period: see fund maturity.

You invest in Company through the Fund. Because the shares of Company are not listed on any stock exchange, and are therefore not publicly tradable, the Fund can only divest if a so-called 'exit' has taken place. This occurs with a) the sale of Company to another company, b) an IPO of Company or c) if there are other buyers of the share. Scenario a) is a decision by Company leading to an automatic exit for you as an investor in the Fund. In scenarios b) and c) the decision of the sale of shares will rest entirely with the Manager of the Fund. It is important to realize that in some cases management cannot force an exit. In such a case, shareholders will hold the share longer. The manager can also decide to pay out "in kind".

Where can I submit a complaint?

If you are not satisfied with the product or with the behavior of its developer or of a person who sells or advises the product, you can submit a written complaint to the Manager SUNU Ventures B.V., Eerste Weteringdwarsstraat 54E, 1017TP Amsterdam, contact@alsinvestmentfund.com Your complaint will be handled carefully and as soon as possible. If the outcome of the complaints procedure is not satisfactory to you, you can submit the complaint to the competent court.

Other useful information

A prospectus is available for the product, which contains all information about the product and describes the associated risks. The manager will make the prospectus of the product available at your request.